title: [Toxicodermia by bendamustine: development of a desensization protocol].
authors.forename: C
authors.initials: C
authors.lastname: Sangrador Pelluz
authors.forename: M M
authors.initials: MM
authors.lastname: Luis Hidalgo
authors.forename: M
authors.initials: M
authors.lastname: Martínez García
authors.forename: M D
authors.initials: MD
authors.lastname: Pérez-Serrano Lainosa
authors.forename: E
authors.initials: E
authors.lastname: Soler Company
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride; D003520:Cyclophosphamide / Q000008:administration & dosage; D003888:Desensitization, Immunologic / Q000379:methods*; D004306:Dose-Response Relationship, Immunologic; D003875:Drug Eruptions / Q000209:etiology* / Q000628:therapy; D005334:Fever / Q000139:chemically induced / Q000628:therapy; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D011537:Pruritus / Q000139:chemically induced / Q000628:therapy; D000069283:Rituximab; D014581:Urticaria / Q000139:chemically induced / Q000628:therapy; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018906:Antineoplastic Agents, Alkylating; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D003520:Cyclophosphamide; D000069461:Bendamustine Hydrochloride; D014740:Vidarabine; C024352:fludarabine